Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Strategy Inc. (MSTR) vs 10X Genomics Inc (TXG) Price & Performance

Strategy Inc.Trade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Strategy Inc. vs 10X Genomics Inc — how do they compare? Strategy Inc. trades at $97.07 (market cap $37.84B), while 10X Genomics Inc trades at $58.7 (market cap $7.61B). The key difference: Strategy Inc. is far larger — about 5× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Strategy Inc. nearer its low. Which is the better fit depends on your goals.

MSTRTXG
Market Cap
$37.84B$7.61B
Sector
TechnologyHealth
52-Week High
$394.39$58.57
52-Week Low
$82.31$11.34
Enterprise Value
$56.61B$7.14B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Strategy Inc.

MSTR trades at $97.33, down 2.68% on the day, with a bearish technical signal and weak fundamentals including a negative net income margin of -6,102.96% and three consecutive quarterly earnings misses. The company's performance remains heavily influenced by its Bitcoin holdings, with recent news highlighting Bitcoin sales to fund stock buybacks and address capital structure concerns.

The outlook is mixed: analyst consensus is bullish with a $210 price target, but high leverage, volatile Bitcoin exposure, and persistent losses pose significant risks. Investment appeal hinges on Bitcoin's recovery and management's ability to stabilize finances, making it speculative for equity investors.

10X Genomics Inc

TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.

Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Strategy Inc.

MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web

Read more on MSTR

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG